Kymera Results Presentation Deck

KT-413 Highly Active on Intermittent Dosing in Preclinical Models Complete Tumor Regressions Associated with Robust IRAK4 and Ikaros/Aiolos Degradation for ~72h +SEM Tumor Volume (mm³) Mean, 2500 2000 1500 1000 500 Drug (Day 33) IV vehicle CC-220, 3 mg/kg, PO, QD x 21 KT-413, 10 mg/kg, IV, D1,2,21,22 7 14 21 28 Days After Start of Treatment CC-220 KT-413 10 mg/kg T/C% (REG%) 9 (94) CR 0 5 PR KYMERA ©2022 KYMERA THERAPEUTICS, INC. 0 2 35 SD 0 0 In the OCI-LY10 MYD88MT xenograft model, intermittent dosing of KT-413 induced strong antitumor activity, including complete regressions. Superior activity compared to IMID CC-220 alone PD 7 0 10000 KT-413 Concentration (ng/ml or ng/g) 1000 100 10 •Tumor PK 48 HAH Plasma PK H IRAK4 Ikaros HH HH 96 Time (hr) 144 192 HHHHH I 240 150 100 50 Single 10 mg/kg dose showed extended tumor exposure and strong degradation of both IRAK4 and IMID substrates that was maintained for least 72hr in preclinical models Target PD 80-90% Ikaros KD and 50-70% IRAK4 KD in tumor for ≥72 hrs to achieve robust anti-tumor activity % of Vehicle Control PAGE 17

View entire presentation